Neuroprotection for hypoxic-ischemic encephalopathy: Contributions from the neonatal research network

Sonia Lomeli Bonifacio, Lina F. Chalak, Krisa P. Van Meurs, Abbot R. Laptook, Seetha Shankaran

Research output: Contribution to journalArticlepeer-review

Abstract

Therapeutic hypothermia (TH) is now well established as the standard of care treatment for moderate to severe neonatal encephalopathy secondary to perinatal hypoxic ischemic encephalopathy (HIE) in infants ≥36 weeks gestation in high income countries. The Neonatal Research Network (NRN) contributed greatly to the study of TH as a neuroprotectant with three trials now completed in infants ≥36 weeks gestation and the only large randomized-controlled trial of TH in preterm infants now in the follow-up phase. Data from the first NRN TH trial combined with data from other large trials of TH affirm the safety and neuroprotective qualities of TH and highlight the importance of providing TH to all infants who qualify. In this review we will highlight the findings of the three NRN trials of TH in the term infant population and the secondary analyses that continue to inform the care of patients with HIE.

Original languageEnglish (US)
Article number151639
JournalSeminars in Perinatology
DOIs
StateAccepted/In press - 2022

ASJC Scopus subject areas

  • Pediatrics, Perinatology, and Child Health
  • Obstetrics and Gynecology

Fingerprint

Dive into the research topics of 'Neuroprotection for hypoxic-ischemic encephalopathy: Contributions from the neonatal research network'. Together they form a unique fingerprint.

Cite this